https://www.biopharm.org.tw
+886-2-2655-8135
services@biopharm.org.twMain Products/ Services/ Pipelines & Platforms
PrecisemAb is committed to developing safer antibody therapy with higher efficacy. Our disease-directed Universal Antibody LockTM is an autologous masking structure on the binding site of an antibody that allows antibody drugs to take effect only in diseased areas, making antibody treatment extraordinarily safe. Compared to competitors, our Lock-antibody ▪ has a higher masking ability and can fully activate the antibody in the diseased area ▪ has low immunogenicity ▪ has a prolonged serum half-life, leading to higher therapeutic efficacy ▪ prevents interfere effect of anti-drug antibody ▪ needs only 5 months for Lock-design and function test We have successfully applied the technology to autoimmune diseases (TNFα and IL-1β) and immuno-oncology therapy (CTLA4, PD-1, 4-1BB). Through providing customized lock-design service and co-developing lock-antibody drugs with you, PrecisemAb aims to create the safest antibody therapy for patients.
Business Interests
▪ Customized Antibody LockTM design service：Antibody lock design and test for your antibody. ▪ In-house developed antibody out-licensing：Lock-EGFR, Lock-PD-1, Lock-CTLA4, Lock-TNFα, Lock-4-1BB, Lock-IL-1β…… ▪ Co-development of lock-antibody drugs
Contact Info
YunChi Lu
CEO
+886-916-822-487
yunchi.lu@precisemab.com